DL-Pyroglutamic acid

DL-Pyroglutamic acid (CAE) as an inactivator of hepatitis B surface, inactivates vaccinia virus, herpes simplex virus, and influenza virus except poliovirus. DL-Pyroglutamic acid is also a possible inhibitor of GABA transaminase, increases GABA amount with antiepileptic action[1][2].

Product Specifications

CAS Number

[149-87-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

GABA Receptor; Influenza Virus

Type

Reference compound

Related Pathways

Anti-infection; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/dl-pyroglutamic-acid.html

Purity

99.21

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1NC(CC1)=O)O

Molecular Formula

C5H7NO3

Molecular Weight

129.11

Precautions

H302, H315, H319, H335

References & Citations

[1]Sugimoto Y, et al. N-alpha-Cocoyl-L-arginine ethyl ester, DL-pyroglutamic acid salt, as an inactivator of hepatitis B surface antigen. Antimicrob Agents Chemother. 1979 Sep;16 (3) :329-32.